We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
  • SKIP TO CONTENT
  • SKIP NAVIGATION
  • Drug & Device Products
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Publications
    • Webinar Training Pass
    • eCFR and Guidances
    • Books
  • Clinical Products
  • Advertising
  • White Papers
  • Contact Us
  • About Us
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account

Postmarket Safety

Home » Topics » Pharmaceuticals » Postmarket Safety
  • January 20, 2023

    Merck Finds Causes of Nitrosamine in Diabetes Drugs

    “The company has already instituted additional quality controls and expects to be able to consistently reduce NTTP levels to meet the long-term acceptable daily intake level this year,” Merck said.
  • January 19, 2023

    Merck Says Nitrosamine Root Cause Identified in Diabetes Drugs

    After a potential carcinogen, Nitroso-STG-19 (NTTP), was found in samples of Merck’s sitagliptin-containing diabetes drugs, the New Jersey drugmaker says it has identified the root cause of the nitrosamine impurity and hopes to fix the issue this year.
  • January 12, 2023

    Spectrum Issues Recall of Epinephrine API Due to Discoloration Reports

    The company has not received any reports of adverse events related to the recall.
Read More
  • December 1, 2022

    FDA Warns Amgen’s Osteoporosis Drug Could Cause Hypocalcemia

  • November 30, 2022

    FDA Warns Amgen’s Osteoporosis Drug Could Cause Severe Hypocalcemia

  • October 18, 2022

    Exela Issues Recall Over Risk of Flying Glass

  • September 14, 2022

    RAPS REPORT: Recall Response — Planning, Communication and Caring Will Build Customer Loyalty, Says Expert

  • August 17, 2022

    Two Children Died After Zolgensma Gene Therapy

  • March 30, 2022

    Diabetes Drug Metformin Linked to 40 Percent Higher Birth Defect Risk, Study Shows

  • March 21, 2022

    Merck KGaA to Pay Over $3 Million to Patients After Thyroid Drug Formulation Change

  • March 11, 2022

    Fresenius Kabi Recalls Sodium Acetate Injection Lots

  • March 7, 2022

    Pfizer Canada Recalls Accuretic Blood Pressure Tablets

  • February 24, 2022

    Large Study Confirms Blood Clots Are Rare After AstraZeneca-Oxford COVID-19 Vaccine

Read More

Products

  • Davidlchesney aqua500

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success – Webinar Recording/Transcript

    $287.00
  • Dennett kouri and faviola michelot 500blue

    Building a World-Class Regulatory Intelligence and Support System – Webinar Recording/Transcript

    $287.00
  • Steve silverman 600red

    Engaging with the FDA: Best Practices for Dealing with Warning Letters, Seizures, Injunctions — and More – Webinar Recording/Transcript

    $287.00
  • Jessica greenbaum 600green

    PDUFA and BsUFA Reauthorization Developments: What Regulatory, Compliance and Quality Professionals Need to Know – Webinar Recording/Transcript

    $287.00
More Products

Events

  • 15Feb

    Advanced Compliance Writing CAPA: Mastering Failure Investigation and Root Cause Analysis

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 22Feb

    Best Practices for Developing and Maintaining a GxP Training Matrix

More
  • Drug Products
    • Quality
    • Regulatory Affairs
    • GMPs
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Device Products
    • Quality
    • Regulatory Affairs
    • QSR
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Clinical Products
    • Trial Design
    • Data Integrity
    • GCP
    • Inspections and Audits
    • Transparency
  • Privacy Policy
  • Do Not Sell or Share My Data
Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Toll free 888.838.5578

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing